SPOTLIGHT -
16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy
50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials